Inactive Instrument

News Durata Therapeutics Inc

Equities

US26658A1079

End-of-day quote Nasdaq Other stock markets
- ^USD	-

2014

Wall St. falls in choppy day; traders wary before earnings

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Durata Therapeutics : Actavis Receives FDA Approval for VIBERZI (eluxadoline) for the Treatment of Irritable Bowel Syndrome with Diarrhea (IBS-D) in Adults	15-06-01	PU
Durata Therapeutics : Infectious Disease Experts, Scientists and Clinicians Join Forces on SHARE ID™ to Accelerate the Battle Against Antibiotic-resistant Infections	15-05-27	PU
Durata Therapeutics : Actavis Confirms Generic Letairis® Patent Challenge	15-04-08	PU
Durata Therapeutics : Actavis Announces Michael R. Gallagher and Peter J. McDonnell to Join Board of Directors	15-04-03	PU
Durata Therapeutics : Actavis and Allergan Shareholders Approve Proposals Related to Actavis' Planned Acquisition of Allergan	15-03-12	PU
Durata Therapeutics : Actavis Confirms District Court Ruling In Atelvia® Patent Litigation	15-03-09	PU
Durata Therapeutics : Actavis Announces Closing of Public Offerings of Ordinary Shares and Mandatory Convertible Preferred Shares in Connection with Pending Acquisition of Allergan	15-03-03	PU
Durata Therapeutics : Actavis Receives Approval from the European Commission for XYDALBA™ (dalbavancin)	15-03-03	PU
Durata Therapeutics : Actavis and Medicines360 Announce FDA Approval of LILETTA™ (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Three Years	15-03-02	PU
Durata Therapeutics : Actavis Receives U.S. FDA Approval for AVYCAZ™ (CEFTAZIDIME-AVIBACTAM)	15-03-02	PU
Durata Therapeutics : Actavis Confirms Generic Uceris® Patent Challenge	15-02-27	PU
Durata Therapeutics : Actavis Receives Final Approval for Generic Version of Subutex®	15-02-25	PU
Durata Therapeutics : Actavis to Divest Doryx® to Mayne Pharma	15-02-18	PU
Durata Therapeutics : Actavis Launches Generic Pulmicort RESPULES®	15-02-17	PU
Durata Therapeutics : Actavis to Divest Rights to Branded Respiratory Portfolio in the U.S. and Canada to AstraZeneca	15-02-09	PU
Durata Therapeutics : Richter and Actavis Announce Positive Phase III Results for Cariprazine in the Prevention of Relapse in Patients with Schizophrenia	15-01-26	PU
Durata Therapeutics : Actavis Launches U.S. Generic Specialty Injectable Portfolio	15-01-20	PU
Durata Therapeutics : Actavis and Allergan Announce Early Termination of Hart-Scott-Rodino Waiting Period for Actavis' Pending Acquisition of Allergan and Record Dates for Shareholder Meetings	15-01-12	PU
Durata Therapeutics : Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR	15-01-12	PU
Durata Therapeutics : Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension	15-01-06	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Durata Therapeutics Inc

Equities

US26658A1079

Summary

Filters